Treats osteoarthritis or rheumatoid arthritis. ANDA 201089, held by Actavis Laboratories FL. Diclofenac Sodium; Misoprostol.
As of Nov 21, 2026, ANDA 201089 (Diclofenac Sodium and Misoprostol), held by Actavis Laboratories FL, was first approved by FDA on Jul 9, 2012, with 2 approved supplements and 0 published complete response letters.
Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. For a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 9, 2012 | Original application | Approved |
| Diclofenac Sodium and Misoprostol50MG;0.2MG · tablet, delayed release;oral | Diclofenac Sodium; Misoprostol | Rx |
| Diclofenac Sodium and Misoprostol75MG;0.2MG · tablet, delayed release;oral | Diclofenac Sodium; Misoprostol | Rx |
| Sep 16, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 16, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 9, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters